PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 3362022

Evoked accelerometry: a sensitive and accurate method for evaluating facial nerve function using a portable device.

D L Zealear·G D Herzon·M Korff
View original source ↗Export metadata ↓

Abstract

A new electrodiagnostic technique has been developed which can be used to monitor facial nerve function. The technique has been termed "evoked accelerometry" (EAC) and is administered by a portable DC powered device. In performing a test, the device stimulates the facial nerve and then measures the evoked muscular response by a small accelerometer sensor affixed to the face with suction. The magnitude of the response is displayed as a digital readout on the device meter. The degree to which a reading is subnormal indicates the extent of nerve degeneration. In a study of normal participants the stimulus-response characteristics of the EAC technique were found to be similar to those of ENoG, indicating the clinical efficacy of the technique. However, evoked accelerometry was found to be more sensitive than ENoG (i.e., detectable response of 0.3% to 0.6% vs. 1.8% to 5.2%) and more accurate than ENoG (average error of 6.8% vs. 13.9% to 20.7%).

Explore related subjects

Biomechanical PhenomenaElectrodiagnosisEvoked PotentialsFacial NerveFemaleHumansMaleNerve DegenerationJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D L Zealear, G D Herzon, M Korff. 1988. Evoked accelerometry: a sensitive and accurate method for evaluating facial nerve function using a portable device.. https://doi.org/10.1288/00005537-198805000-00019

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1995

Characterization of the unique mechanism mediating the shear-dependent binding of soluble von Willebrand factor to platelets.

We have studied the mechanism of interaction between soluble von Willebrand factor (vWF), labeled with fluorescein isothiocyanate (FITC), and platelets exposed to shear in a cone-and-plate viscometer. A flow cytometer calibrated with fluorescent bead standards was used to calculate the number of molecules associated with each platelet in suspension. To validate the methods and reagents used, binding of the same labeled vWF was assessed in the presence of ristocetin or alpha-thrombin and found to be saturable, with a narrow and symmetric distribution on > 90% of the platelets. As expected, essentially all bound ligand interacted exclusively with platelet membrane glycoprotein (GP) Ib alpha in the presence of ristocetin and with GP IIb-IIIa after stimulation with alpha-thrombin. In contrast, only a minor proportion (< 20%) of the platelets exposed to shear were found to bind vWF, with no evidence for saturation and markedly decreased interaction when the platelet count was below 100,000 microliters. Moreover, shear-induced vWF binding was blocked equally effectively by selected monoclonal antibodies against either GP Ib alpha or GP IIb-IIIa or against the respective binding sites in vWF. Thus, both receptors are involved in the process, possibly through initial transient interactions mediated by GP Ib alpha that lead to platelet activation and subsequent irreversible binding supported by GP IIb-IIIa. While the levels of shear stress theoretically applied to platelets in these experiments are above those thought to occur in the normal circulation, our findings demonstrate a unique vWF binding mechanism that is not mimicked by other known modulators and correlates with platelet aggregation. Similar processes may occur in response to lower shear stress when platelets are exposed to thrombogenic surfaces and agonists generated at sites of vascular injury during thrombus formation.

Biomechanical Phenomena↗